Matthew McCurdy
Cardiovascular Disease · Dothan, ALNPI 1134625726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,409, 4.9 times the $287 reported in 2021.
Across 207 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$772
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$313
- Amgen$310
- Pfizer$307
- Abbott$244
- Chiesi USA, Inc.$200
- plus $2K from 36 others
What the payments were for
- Food & beverage$4,057100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 32 | $772 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $313 |
| Amgen | 19 | $310 |
| Pfizer | 25 | $307 |
| Abbott | 13 | $244 |
| Chiesi USA, Inc. | 7 | $200 |
| Penumbra, Inc. | 3 | $148 |
| Sanofi-aventis U.S. LLC | 4 | $136 |
| AstraZeneca | 9 | $134 |
| Medtronic | 2 | $130 |
| Boehringer Ingelheim | 3 | $123 |
| Grifols USA, LLC | 8 | $117 |
| Philips North America LLC | 8 | $117 |
| Novartis | 5 | $79 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $67 |
| Heartflow, Inc. | 4 | $66 |
| Merck | 4 | $65 |
| Johnson & Johnson | 3 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Alnylam Pharmaceuticals Inc. | 3 | $54 |
| Terumo Medical Corporation | 1 | $53 |
| Vifor Pharma, Inc. | 2 | $52 |
| La Jolla Pharmaceutical Company | 3 | $52 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Livanova USA, Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $33 |
| Edwards Lifesciences | 1 | $33 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Shockwave Medical, Inc | 1 | $24 |
| Atricure, Inc. | 1 | $22 |
| GE HealthCare | 1 | $21 |
| Bayer | 1 | $20 |
| Stryker | 1 | $20 |
| Thrombolex, Inc. | 1 | $19 |
| ZOLL Circulation Inc | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Biogen | 1 | $14 |
| UCB, Inc. | 1 | $13 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$256
- Indigo System$112
- LifeVest$111
- SYMPLICITY G3$101
How this compares
$4,077 in reported general payments places this provider in the 60th percentile of 292 cardiovascular disease providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrilintaTicagrelor | 55 | $29,920 |
| Dofetilide | 11 | $1,051 |
| ClopidogrelClopidogrel Bisulfate | 31 | $205 |
| Nitroglycerin | 30 | $176 |
| Atorvastatin Calcium | 29 | $166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta | $134 | $29,92055 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Dothan
- Anjula ChibDothan$27K
- Andreas MuenchDothan$18K
- Darius AliabadiDothan$11K
- Dennis ThomasMobile$894K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.